In another sign of biopharma's waning interest in the traditional ex vivo gene therapy approach, CSL Behring is shutti | CSL ...
Based on a small trial with positive muscle performance data, Regenxbio is expected to pursue approval of its gene therapy ...
Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
In an update posted today, Neurogene said that the "emerging treatment-related serious adverse event (SAE)" was a case of ...
Neurogene is proceeding with a scaled-back study of its proposed NGN-401 gene therapy for the rare genetic neurological disorder Rett syndrome after a serious adverse event left a study participant in ...
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
The 11th Cell Biology Industry Conference (CBIC) opened in Beijing, attracting more than 3,000 guests from clinical research ...
Healthcare Asia on MSN10h
Global regenerative medicine market to grow by $70.11b by 2028It is driven by developments in personalised medicine, gene therapy, and CRISPR technology. The global regenerative medicine ...
The US FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating acute leukaemia with KMT2A translocation.
Biohacking is not now limited to tech-savvy rebels, it is an experiment on human evolution itself. Whether we are ready to face the music or not, biohacking is already at our doorstep. While ...
TipRanks on MSN7h
Oxford Biomedica Strengthens Board with Key AppointmentOxford BioMedica (GB:OXB) has released an update. Oxford Biomedica has appointed Colin Bond as a Non-Executive Director, effective January 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback